Viking Therapeutics has experienced a share price increase of 20% over the last month. This comes amidst the company's report of increased financial losses, with a net loss of $46 million in Q1 2025, up from $27 million the previous year, and a change in their auditing firm from Marcum to CBIZ. While these company-specific events likely added some pressure, broader market trends including a significant S&P 500 rally, driven by optimistic earnings reports and potential easing of U.S.-China trade tensions, may have supported the positive movement in Viking Therapeutics' stock, aligning it with an overall upward market trajectory.

Be aware that Viking Therapeutics is showing 4 weaknesses in our investment analysis and 2 of those are concerning.NasdaqCM:VKTX Earnings Per Share Growth as at May 2025

The latest GPUs need a type of rare earth metal called Terbium and there are only 23 companies in the world exploring or producing it. Find the list for free.

Over the past three years, Viking Therapeutics' shares have experienced a very large total return of 1077.57%, highlighting substantial market performance. However, in the more recent one-year period, the company's stock underperformed the broader US market, which saw a 9.5% return, and also lagged behind the US Biotechs industry, which experienced a 6.6% decline. This indicates the company has shown better performance over the longer term despite recent challenges.

The introduction highlighted a few key financial and operational events, including a switch in auditors and increased financial losses, which could impact revenue and earnings forecasts adversely. The forecasted revenue growth of 69.62% annually is a strong point, though uncertainty remains around achieving profitability in the near future. The recent 20% rise in share price may reflect optimism, possibly linked to broader market trends or analyst expectations. It's important to consider the current price in context with the consensus analyst price target of US$90.26, which is notably higher than the current price, indicating a potential valuation discrepancy. However, analysts are not in a statistically confident range of agreement, which introduces some uncertainty regarding these estimations.

The analysis detailed in our Viking Therapeutics valuation report hints at an inflated share price compared to its estimated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NasdaqCM:VKTX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments